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| INTRODUCTION
Fixed-ratio combinations (FRCs) of basal insulin (BI) and a glucagonlike peptide-1 receptor agonist (GLP-1RA) are a relatively recent addition to the treatment intensification options for type 2 diabetes (T2D), with demonstrated efficacy and tolerability compared to either treatment alone. 1, 2 iGlarLixi is a titratable FRC of insulin glargine U100
(iGlar) and the short-acting GLP-1RA lixisenatide (Lixi), administered as a single daily injection. 3, 4 iGlarLixi provides complementary effects, with iGlar primarily improving fasting plasma glucose (FPG), and Lixi reducing postprandial plasma glucose via enhanced glucosestimulated insulin secretion, suppression of glucagon secretion and delayed gastric emptying. 2, 5 In the LixiLan-O and LixiLan-L trials, which evaluated iGlarLixi in patients with T2D uncontrolled on oral antidiabetic drugs (OADs) or on BI, respectively, patients on iGlarLixi demonstrated improved glycaemic control compared with those taking iGlar, without weight gain or increased risk of hypoglycaemia. 2, 6 The safety profile of iGlarLixi was consistent with those of its components, but the GLP-1RA-associated gastrointestinal effects were lower compared with lixisenatide. 2, 6 In both LixiLan-O and LixiLan-L, patients on iGlarLixi showed greater reductions in glycated haemoglobin (HbA1c) from baseline to study end at 30 weeks compared with those on iGlar (LixiLan-O: 2 | METHODS
| Trial designs
The full methodologies of the LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were described previously 2, 6 and are summarized in Figure S1 and the Supporting Information Methods, Appendix S1. 
| Post hoc analysis

| Statistical analysis
Responder analysis was based on the modified intention-to-treat during the study, the patient was censored at his/her last study visit.
Time-to-control analysis was based on the mITT population. P values were calculated using the stratified log-rank test. Hazard ratios (HRs)
were estimated using a stratified Cox regression model with treatment as the model factor and stratified by the randomization strata.
3 | RESULTS
| Patient baseline characteristics
In LixiLan-O, 469 and 467 patients were randomized to the iGlarLixi and iGlar groups, respectively. In LixiLan-L, 367 and 369 patients were randomized to the iGlarLixi and iGlar groups, respectively. Patient baseline characteristics in both studies have been described previously 2,6 and were similar across treatment groups within each trial (Table S1 , Appendix S1).
| Efficacy and hypoglycaemia outcomes at week 12 3.2.1 | Changes in HbA1c from baseline
In both LixiLan-O and LixiLan-L, patients achieved a greater reduction in HbA1c from baseline to week 12, and lower mean HbA1c at week 12 with iGlarLixi than with iGlar (Table 1) ; indeed, in LixiLan-O, mean
HbA1c at week 12 with iGlarLixi had already reached the target:
<53 mmol/mol (<7%; ie, 51.1 ± 8.1 mmol/mol [6.8% AE 0.7%]).
| Changes in FPG and SMPG
In LixiLan-O and LixiLan-L, the mean FPG at week 12 was comparable between treatment groups, and was below the 2015 ADArecommended target 7 of ≤7.2 mmol/L (≤130 mg/dL). In both trials, reductions in FPG from baseline were similar between treatment groups (Table 1) , and mean change in average 7-point SMPG at week 12 was greater with iGlarLixi than with iGlar ( Table 1 ). The differences in mean SMPG between the iGlarLixi and iGlar groups were pronounced at postmeal time points ( Figure S2 and Table S2 , Appendix S1).
| Insulin dose
Mean insulin doses at week 12 were similar for iGlarLixi vs iGlar within each trial (Table 1) .
| Body weight
iGlarLixi mitigated body weight gain compared with iGlar alone in both studies (Table 1) . <53 mmol/mol (<7%) at 8 and 12 weeks with iGlarLixi than with iGlar (P < .0001; Table 2 ). The proportions of patients with assessments available at 8 and 12 weeks were similar between the iGlarLixi and iGlar groups, and the amount of missing data was small (ranging from 2% to 3.5%; Table S3 , Appendix S1).
| Hypoglycaemia outcomes
| Time to control
In LixiLan-O, the HbA1c target was achieved by 50% of patients in approximately half the time with iGlarLixi vs iGlar (median time 85.0 vs 166.0 days; HR 1.5; P < .0001 [ Table 2 and Figure S3A , Appendix S1]). In LixiLan-L, the median time to achieve HbA1c <53 mmol/mol (<7%) was 153.0 days with iGlarLixi, whereas the target was not reached by 50% of patients with iGlar during the study period (HR 2.1; P < .0001 [ Table 2 and Figure S3B , Appendix S1]).
In both trials, the proportions of patients achieving FPG ≤7.2 mmol/L (≤130 mg/dL) were similar between treatment arms ( Table 2 ). The median time to achieve target FPG was similar with iGlarLixi vs iGlar in LixiLan-O, while in LixiLan-L, the FPG target was already achieved by >50% of patients at baseline in the iGlarLixi and iGlar groups (following at least 6 months of BI therapy prior to trial enrolment and a 6-week run-in phase with iGlar; Table 2 ; Figure S3C and D, Appendix S1). Change from baseline to week 12 −0.6 AE 2. At week 12 54.6 ± 8.8 (7.1 ± 0.8)
| DISCUSSION
59.1 ± 9.4 (7.6 ± 0.9)
Change from baseline to week 12 -10.1 ± 7.7 (-0.9 ± 0.7)
At week 12 7.0 AE 1.9 6.9 AE 1.9
Change from baseline to week 12 −0.3 AE 2.3 −0.5 AE 2. Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; iGlar, insulin glargine U100; iGlarLixi, insulin glargine and lixisenatide; mITT, modified intention-to-treat; SMPG, self-measured plasma glucose.
a Data are mean AE SD, based on mITT population.
b Hypoglycaemia events occurring on or before study day 84.
c Number of patients (%) with events, based on safety population. present paper were observed with IDegLira, an FRC of insulin degludec and the long-acting GLP-1RA liraglutide. In a post hoc analysis, IDegLira reduced plasma glucose faster and to a greater extent than its components within the first 12 weeks of therapy, without weight gain or an increased risk of hypoglycaemia. 8 Together, these results support the hypothesis that FRCs allow patients with T2D to achieve glycaemic targets earlier than with insulin alone.
Despite the importance of early glycaemic control, 9-11 clinical inertia is common for patients with inadequate response to OADs, BI or GLP-1RAs. [12] [13] [14] In a retrospective analysis of patients with T2D
and inadequate glycaemic control despite ≥2 non-insulin antidiabetic drugs, lack of treatment intensification was observed in 1 out of 5 patients followed up by primary care physicians, and the median time to first intensification was 17 months in patients with HbA1c
>8.0%-9.9%, and 10 months in those with HbA1c >10%. 15 In addition to improvement in efficacy, FRC treatment with BI and a GLP-1RA offers simplified titration and administration. These factors, along with low rates of hypoglycaemia, the potential for mitigation of insulininduced weight gain and a favourable gastrointestinal tolerability profile, may help combat clinical inertia, improve patient satisfaction and persistence, and minimize periods of hyperglycaemia often associated with the approach of adding on therapies in a sequential manner.
One limitation of the present analysis is that it was performed post hoc; therefore, the sample size and power calculations performed to address the studies' primary endpoints may not apply to this analysis. Ideally, these findings would be further validated by prospectively planned studies that focus on early efficacy and durability. Additionally, the present study examined patients enrolled in clinical trials;
follow-up of trial populations tends to be different from that performed in routine clinical practice. Pragmatic real-world studies will be required to confirm early glycaemic control in more patients with iGlarLixi vs BI in everyday clinical practice.
In conclusion, iGlarLixi allows more patients intensifying either
OADs or BI to achieve glycaemic control at early treatment time points (8 and 12 weeks) than BI alone. The efficacy, low rates of hypoglycaemia and the treatment simplicity with this FRC may help to address clinical inertia and allow more patients to safely reach their glycaemic targets earlier.
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